Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.46 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3441833 | 0.87 | MAPK1 (0.43) | GSK3BMAPK14ADORA1EGFRRAF1 | |
| SCHEMBL12997420 | 0.87 | GSK3B (0.50) | GSK3BMAPK14ADORA1EGFRRAF1 | |
| SCHEMBL3763020 | 0.86 | GSK3B (0.42) | GSK3BMAPK14ADORA1EGFRRAF1 | |
| SCHEMBL8810385 | 0.84 | ADORA2A (0.53) | GSK3BMAPK14ADORA1EGFRRAF1 | |
| SCHEMBL22095478 | 0.83 | MAPK14 (0.49) | GSK3BMAPK14MAPK1CDK2MAPK9 | |
| SCHEMBL14515749 | 0.82 | MAPK14 (0.41) | GSK3BMAPK14ADORA1EGFRRAF1 | |
| SCHEMBL3534340 | 0.82 | MAPK1 (0.41) | GSK3BMAPK14ADORA1EGFRRAF1 | |
| SCHEMBL3542508 | 0.82 | GSK3B (0.46) | GSK3BMAPK14ADORA1EGFRRAF1 | |
| SCHEMBL14515544 | 0.82 | SLC2A1 (0.45) | GSK3BMAPK14ADORA1EGFRRAF1 | |
| SCHEMBL13105284 | 0.82 | SLC2A1 (0.47) | GSK3BMAPK14ADORA1EGFRRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20220073512-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3893879-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020123925-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123925-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-0379979-B1 | Pyrazolopyridine compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-03-19 | — | — | EP | disclosed |
| US-5155114-A | Treating or preventing renal toxicity, nephrosis, nephritis | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| US-4985444-A | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| EP-0379979-A1 | Pyrazolopyridine compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073512-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | MAP3K3, MAP2K3, MAP3K2 | GSK3B 234/4885MAPK14 53/4885ADORA1 3193/4885 |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | MAP3K1, MAP3K3, MAPK1 | GSK3B 67/4885MAPK14 195/4885ADORA1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.